Best HSDD Medications: Comparing Your Options

If your desire feels muted, disconnected, or simply gone—you’re not imagining it. Hypoactive Sexual Desire Disorder affects many women, with prevalence climbing to 40-55% during the menopausal transition. You may love your partner deeply yet rarely feel that spark of wanting. You might remember when intimacy felt effortless—and wonder what happened. The frustrating truth? Most treatments designed for low libido were created with male sexuality in mind. They address one piece of desire while ignoring how women’s arousal actually works—through both neurochemical pathways and emotional connection. That’s why so many women try treatment after treatment without finding real relief. At Inner Balance, we developed Libida™ specifically because existing options kept falling short. Our dual-pathway approach combines bremelanotide (an FDA-approved active ingredient for desire in its injectable form) with oxytocin (for bonding and emotional readiness)—reflecting how female sexuality actually functions. For women whose hormones also need attention, our Oestra™ hormone therapy provides the foundational support that can make desire-focused treatments work even better.

Key Takeaways

• HSDD is the most common female sexual dysfunction, affecting up to 55% of postmenopausal women and causing significant personal distress
• Libida™ is the only HSDD treatment combining bremelanotide and oxytocin, addressing both the neurochemical spark and emotional connection pathways
• FDA-approved options exist (Vyleesi, Addyi) but require injections or daily pills with alcohol restrictions
• Single-pathway treatments miss half the equation—most medications boost dopamine but ignore the bonding and emotional safety aspects of female desire
• Hormone optimization matters but doesn’t always restore desire on its own; Libida™ works whether or not you’re on hormone therapy
• Cost varies dramatically: from approximately $8-10 per experience with Libida™ to higher costs with injectable alternatives
• Treatment timing matters—on-demand options allow for spontaneity, while daily medications require 8-12 weeks before showing effects

1. Libida™ On-Demand Desire Support

When it comes to treating HSDD comprehensively, Libida™ from Inner Balance stands alone. It’s the first women-first libido solution that addresses both the neurochemical desire pathways and the emotional connection that shapes how women actually experience arousal.

Why Libida™ Works Differently

Most HSDD treatments target dopamine alone—the “wanting” signal in your brain. But female desire isn’t just about wanting. It involves feeling emotionally safe, connected, and relaxed enough to receive arousal cues. Libida™ addresses both:

Bremelanotide activates melanocortin receptors (MC4R) in the hypothalamus, boosting dopamine, motivation, sexual thoughts, anticipation, and arousal. This is the same active ingredient used in the FDA-approved injectable treatment Vyleesi—but delivered in a convenient sublingual tablet.

Oxytocin activates bonding and emotional-safety pathways, supporting connection, closeness, emotional readiness, relaxation into intimacy, and relational warmth. No other HSDD medication includes this component.

Together, they reflect how women’s sexuality actually works—not the male-centric model that designed most existing treatments.

Clinical Evidence Supporting Libida™’s Approach

The bremelanotide component in Libida™ has demonstrated meaningful benefits in clinical trials:

• Increased desire and arousal
• More satisfying sexual events
• Reduced distress related to low desire
• Restored sexual fantasies and responsiveness

How to Use Libida™

• Form: Tiny sublingual lozenge (dissolves under tongue—no injection needed)
• Timing: Take 45-60 minutes before anticipated intimacy
• Duration: Effects may last 24-72 hours
• Frequency: Use as needed, on-demand
• Compatibility: Non-hormonal; works whether or not you’re using hormone therapy

What Sets Libida™ Apart

Administration: Sublingual tablet versus injections or daily pills with other treatments

Pathways targeted: Dopamine plus oxytocin (dual pathway) versus dopamine only (single pathway) for alternatives

Timing: On-demand use versus daily requirement or injections

Cost per use: Approximately $8-10 versus higher costs for alternatives

Emotional connection support: Yes, unlike other HSDD medications

Pricing and Access

• One-time purchase: $249 for 10 tablets
• Subscription options: $199 for 1-month supply (10 tablets), $249 for 2-month supply (20 tablets), $299 for 3-month supply (30 tablets)
• HSA/FSA eligible
• Telehealth consultation included

Libida™ contains the same FDA-approved active ingredient used in the injectable treatment for HSDD, compounded for off-label use under clinician guidance in a dual-action formula.

Who It’s Best For: Women whose desire feels muted or missing—especially those who’ve tried hormone therapy without full resolution, or who want a non-hormonal, brain-first option that addresses both the spark and the emotional component of intimacy.

2. Vyleesi (Bremelanotide Injection)

Vyleesi was the second FDA-approved medication for HSDD in premenopausal women (2019). It contains bremelanotide, the same active ingredient found in Libida™, delivered via subcutaneous injection.

How It Works

Bremelanotide activates melanocortin receptors in the brain, increasing dopamine activity in areas associated with sexual desire and motivation. Clinical trials showed statistically significant improvements in desire and reduction in distress.

Practical Considerations

• Administration: Self-injection into abdomen or thigh, 45 minutes before sexual activity
• Frequency limit: Maximum 8 doses per month; no more than once per 24 hours
• Common side effects: Nausea (approximately 40%), flushing (around 20%), headache (approximately 14%)

Pros

• FDA-approved with clinical trial data
• On-demand use (only when needed)
• Immediate same-day effects

Limitations

• Requires injection—many women find self-injecting uncomfortable or inconvenient
• High nausea rate (around 40%) often decreases with repeated use but can be discouraging initially
• No oxytocin component—addresses dopamine pathway only, missing the emotional connection piece
• Only approved for premenopausal women (postmenopausal efficacy still being studied)

Who It’s Best For: Premenopausal women comfortable with self-injection who prefer an FDA-approved product and have insurance coverage or flexible spending accounts.

3. Addyi (Flibanserin)

Addyi made history in 2015 as the first FDA-approved medication for HSDD in premenopausal women. It remains an important option for women seeking daily oral medication.

How It Works

Flibanserin works differently than bremelanotide. It’s a serotonin receptor modulator that decreases serotonin while increasing dopamine and norepinephrine in brain regions associated with sexual desire and reward processing. Unlike on-demand treatments, it must be taken daily to build effectiveness.

Practical Considerations

• Administration: 100mg oral tablet taken at bedtime daily
• Timeline: 4-8 weeks before initial improvement; 12 weeks for maximal effects
• Black box warning: Alcohol timing matters due to hypotension/fainting risk: patients are typically advised to wait at least 2 hours after 1–2 drinks before taking it at bedtime, skip the dose if they’ve had 3+ drinks that evening, and avoid alcohol until the next day.
• Common side effects: Dizziness (approximately 11-17%), sleepiness (around 11%), nausea (approximately 10%)

Pros

• FDA-approved for premenopausal women
• Oral tablet (no injection)
• May help women who don’t respond to other treatments

Limitations

• Daily medication requirement—must take every day whether or not intimacy is planned
• Strict alcohol prohibition—a black box warning that limits lifestyle flexibility
• Weeks to work—8-12 weeks before seeing benefits versus same-day effects
• Different mechanism—doesn’t include the dopamine-boosting melanocortin activation or oxytocin
• Drug interactions—cannot use with certain medications

 

Who It’s Best For: Women who prefer daily oral medication, rarely drink alcohol, and want an FDA-approved option that doesn’t require injection.

4. Compounded PT-141 (Bremelanotide)

Several telehealth platforms offer compounded versions of bremelanotide (PT-141), the same active ingredient in Vyleesi and Libida™. These are prepared by compounding pharmacies and used off-label.

Available Options

• Injectable formulations: Most common; similar to Vyleesi but often less expensive
• Troches (lozenges): Some compounders offer sublingual options
• Pricing: Varies by provider and formulation

Pros

• Generally less expensive than brand-name Vyleesi
• Multiple providers offer telehealth access
• Some offer non-injection formats

Limitations

• No oxytocin component—single-pathway approach only
• Quality inconsistency—compounding pharmacies vary in standardization and testing
• No dual-action formula—cannot match Libida™’s combined bremelanotide and oxytocin approach
• Many still require injection—troches available but quality varies
• Limited oversight—not subject to the same regulatory scrutiny as FDA-approved products

Who It’s Best For: Cost-conscious women who have researched specific compounding pharmacies and are comfortable with off-label use.

5. Testosterone Therapy

Testosterone therapy for HSDD is supported by international medical society consensus, particularly for postmenopausal women. While no testosterone product is FDA-approved for women in the United States, clinical guidelines from multiple organizations recommend it as evidence-based treatment.

How It Works

Testosterone modulates sexual behavior by increasing dopamine in the central nervous system and supporting genital tissue structure and function. Women naturally produce testosterone, but levels decline with age—especially after surgical menopause.

Clinical Evidence

Meta-analyses show testosterone therapy provides approximately 1 additional satisfying sexual event per month compared to placebo, along with improvements in desire, arousal, and orgasm.

Practical Considerations

• Administration: Transdermal gel or cream applied daily or every other day
• Dosing: Approximately one-tenth of male dosing
• Monitoring required: Baseline and follow-up testosterone levels, liver function, lipids
• Timeline: 4-12 weeks before seeing improvement

Pros

• Strong evidence base with international guideline support
• Relatively affordable
• May address multiple aspects of sexual function

Limitations

• Off-label in the US—requires prescriber comfortable with guideline-based prescribing
• Requires ongoing monitoring—lab work every 3-6 months initially
• Potential side effects—acne, hair growth; rarely voice changes if overdosed
• Not everyone responds—some women need additional targeted treatment

For women who need foundational hormone support beyond testosterone, Inner Balance’s Oestra™ provides comprehensive bioidentical estradiol and progesterone—which can work synergistically with Libida™ for complete support.

Who It’s Best For: Postmenopausal or surgically menopausal women with HSDD who have access to a prescriber knowledgeable about women’s testosterone therapy and are willing to undergo monitoring.

6. Bupropion and Buspirone

These medications are sometimes prescribed off-label for HSDD, particularly when low desire is related to antidepressant use.

Bupropion (Wellbutrin)

A norepinephrine-dopamine reuptake inhibitor primarily used for depression. Unlike SSRIs, it doesn’t increase serotonin—and may actually improve sexual function in some women.

• Best for: Women with SSRI-induced sexual dysfunction or comorbid depression
• Administration: 150-300mg daily (oral)

Buspirone

An anxiolytic that may help with desire, particularly for women on SSRIs.

• Best for: Women with anxiety and SSRI-induced dysfunction
• Administration: Can be taken before sexual activity or daily

Limitations

• Limited HSDD-specific evidence—better data for reversing SSRI effects than treating primary HSDD
• Different mechanism—don’t target the specific melanocortin pathways proven to increase female desire
• No oxytocin component—miss the emotional connection aspect entirely
• Bupropion carries seizure risk in certain populations

Who They’re Best For: Women whose low desire is directly linked to SSRI/SNRI antidepressant use, who want to keep their current medication while addressing sexual side effects.

7. Foundational Hormone Therapy

Sometimes low desire stems from broader hormonal imbalance—particularly declining estradiol and progesterone during perimenopause and menopause. Optimizing these hormones can create the physiological foundation that makes desire-focused treatments more effective.

How Hormone Therapy Supports Sexual Function

Estradiol supports vaginal tissue health, lubrication, and blood flow—reducing painful intercourse that often causes women to avoid intimacy. Progesterone supports mood stability, sleep, and stress regulation—all of which influence desire indirectly.

Inner Balance’s Oestra™ delivers both bioidentical estradiol and progesterone through vaginal application, achieving higher bioavailability than oral hormones while bypassing liver metabolism.

The Oestra™ and Libida™ Approach

For women whose hormones are already optimized but desire still feels flat, Libida™ serves as the “missing piece.” This combination addresses:

• Foundational hormone balance (Oestra™) supports vaginal health, mood, sleep, metabolism
• Neurological desire amplification (Libida™) targets the brain where female desire actually originates

Why Hormone Therapy Alone May Not Be Enough

Many women optimize their hormones yet still experience low desire. That’s because HSDD involves central nervous system pathways that hormone therapy doesn’t directly address. Libida™ fills this gap with targeted brain-acting peptides.

Who It’s Best For: Women experiencing multiple perimenopausal or menopausal symptoms who want comprehensive support—combining foundational hormone optimization with targeted desire enhancement when needed.

Why Most HSDD Treatments Fall Short

The pattern is clear: most HSDD medications address only one aspect of female sexuality while ignoring others.

Single-pathway approaches target dopamine but miss oxytocin’s role in bonding and emotional safety. Women report feeling “chemically turned on” but still disconnected from their partners—because the emotional pathway wasn’t activated.

Male-centric design shaped early HSDD treatments. The assumption that desire works the same way in women as men led to medications that miss half the equation.

Inconvenient administration creates barriers. Injections, daily pills with alcohol restrictions, and lengthy timelines to effectiveness all reduce real-world adherence and satisfaction.

Fragmented care forces women to piece together multiple treatments—hormone therapy from one provider, desire medication from another, therapy from a third—without integration.

Libida™ was designed differently: acknowledging that female desire involves both neurochemical activation and emotional readiness, delivered in a format that fits real life.

The Bottom Line

Effective HSDD treatment exists—but not all options are equal.

Libida™ earns the top position for its unique dual-pathway approach, combining bremelanotide’s proven desire-boosting effects with oxytocin’s bonding support. At approximately $8-10 per experience with no injections required, it represents both the most comprehensive and most accessible option available.

FDA-approved alternatives have their place: Vyleesi for those who prefer injectable format with regulatory backing, Addyi for those comfortable with daily medication and alcohol abstinence.

Hormone optimization through Oestra™ can provide foundational support that makes desire-focused treatments work better—especially for women experiencing broader perimenopausal or menopausal symptoms.

The most important step? Recognizing that your low desire has a biological basis and real solutions exist. You don’t have to accept a diminished intimate life as inevitable.

Frequently Asked Questions

What makes Libida™ different from other HSDD medications?

Libida™ is the only HSDD treatment combining bremelanotide (which boosts dopamine and desire) with oxytocin (which supports bonding and emotional connection). This dual-pathway approach reflects how female sexuality actually works—through both neurochemical activation and emotional readiness. Other treatments address only one pathway, which is why many women find them incomplete.

Can I use Libida™ if I’m already on hormone therapy?

Yes. Libida™ is non-hormonal and compatible with any hormonal status. Many women use it alongside Oestra™ or other hormone therapies. In fact, this combination addresses both foundational hormone balance and targeted desire enhancement—a comprehensive approach that’s often more effective than either alone.

Why is vaginal delivery better for hormone therapy?

Vaginal delivery achieves higher bioavailability than oral hormones by bypassing liver metabolism. This means more of the active hormone reaches your bloodstream with fewer metabolic byproducts. For desire specifically, Libida™’s sublingual delivery allows the active ingredients to absorb directly through the mucous membranes—avoiding the digestive system entirely.

How quickly can I expect results from HSDD treatment?

This varies by treatment type. Libida™ and Vyleesi work on-demand, with effects beginning 45-60 minutes after use. Addyi requires 4-8 weeks of daily use before improvement, with full effects at 12 weeks. Testosterone therapy typically shows results in 4-12 weeks. The on-demand options provide immediate feedback about whether the treatment is working for you.

What if I’ve tried other treatments without success?

This is actually common—and often happens because previous treatments addressed only part of the problem. If you’ve tried dopamine-focused medications without full results, you may benefit from Libida™’s added oxytocin component. If you’ve optimized hormones but desire still lags, a brain-acting option like Libida™ may provide the targeted support you need. Our clinical team can help identify which approach makes sense for your specific situation.

Is Libida™ FDA-approved?

Libida™ contains bremelanotide, which is FDA-approved in its injectable form (Vyleesi) for premenopausal women with HSDD. Libida™ is compounded for off-label use under clinician guidance, combining this proven ingredient with oxytocin in a convenient sublingual format. This allows us to offer a dual-action approach that no FDA-approved product currently provides.